Expert Review of Anti-infective Therapy最新文献_第3页

Letter to the editor regarding "Alternative drugs for the treatment of gonococcal infections: old and new" Expert Review of Anti-infective Therapy. 2024. 22(9):753-759. 关于“治疗淋球菌感染的替代药物：新旧”的致编辑信抗感染治疗专家评论。2024。22日(9):753 - 759。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-08 DOI: 10.1080/14787210.2025.2502799

Alison Luckey, David Altarac, Sarah M McLeod

引用次数: 0

Challenges in preserving antibiotic effectiveness: time for a novel approach. 保持抗生素有效性的挑战：是时候采用新方法了。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-06 DOI: 10.1080/14787210.2025.2499472

Ashley Collazo, Larissa Grigoryan, Aanand D Naik, Barbara W Trautner

引用次数: 0

Incidence and predictors of linezolid-associated thrombocytopenia in critically ill patients: nomogram development based on comprehensive screening of over 70 factors. 危重患者利奈唑胺相关血小板减少症的发病率和预测因素：基于70多种因素综合筛选的线图发展

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-05 DOI: 10.1080/14787210.2025.2500589

Abdel-Hameed Ebid, Mohamed Abdeltawab, Osama Ahmed, Mohamed A Mobarez, Mahmoud Ibrahim

{"title":"Incidence and predictors of linezolid-associated thrombocytopenia in critically ill patients: nomogram development based on comprehensive screening of over 70 factors.","authors":"Abdel-Hameed Ebid, Mohamed Abdeltawab, Osama Ahmed, Mohamed A Mobarez, Mahmoud Ibrahim","doi":"10.1080/14787210.2025.2500589","DOIUrl":"https://doi.org/10.1080/14787210.2025.2500589","url":null,"abstract":"Background: Linezolid-associated thrombocytopenia (LAT) is a significant complication in intensive care unit (ICU) patients, increasing bleeding risk and leading to treatment discontinuation. This study aims to assess LAT incidence, identify risk and protective factors, and develop a predictive nomogram.Research design and methods: This retrospective cohort study included 422 adult ICU patients treated with linezolid. Over 70 clinical, demographic, laboratory, and therapeutic variables were analyzed. Logistic regression identified key risk and protective factors for LAT, and a nomogram was developed for risk prediction.Results: LAT occurred in 39.8% of patients. Risk factors included linezolid therapy > 10 days (OR 5.80, p < 0.01), solid organ tumor (OR 2.18, p = 0.03), hemodialysis (OR 5.12, p < 0.01), elevated lactate (OR 1.13, p = 0.03), and vasopressor use (OR 4.48, p < 0.01). Protective factors were surgery (OR 0.34, p < 0.01), IV N-acetylcysteine (OR 0.12, p < 0.01), oral N-acetylcysteine (OR 0.17, p < 0.01), higher baseline platelets (OR 0.79, p = 0.05), and acetaminophen (OR 0.42, p < 0.01). The nomogram showed strong discrimination (AUC 0.834, p < 0.001).Conclusions: LAT is common in ICU patients and associated with adverse outcomes. Prolonged therapy, solid organ tumors, dialysis, high lactate, and vasopressor use increase risk; high platelet counts, N-acetylcysteine, and IV acetaminophen decrease risk. External validation and prospective trials are warranted.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"1-13"},"PeriodicalIF":4.2,"publicationDate":"2025-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143999196","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The ongoing challenge of prevention of pertussis in infants: what's new in 2024? 预防婴儿百日咳的持续挑战：2024年有什么新进展？

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-01 Epub Date: 2025-03-09 DOI: 10.1080/14787210.2025.2476010

Maria Gabriella Matera, Carlo Capristo, Vito de Novellis, Mario Cazzola

{"title":"The ongoing challenge of prevention of pertussis in infants: what's new in 2024?","authors":"Maria Gabriella Matera, Carlo Capristo, Vito de Novellis, Mario Cazzola","doi":"10.1080/14787210.2025.2476010","DOIUrl":"10.1080/14787210.2025.2476010","url":null,"abstract":"Introduction: Pertussis, a respiratory disease caused primarily by Bordetella pertussis, is undergoing a resurgence despite decades of high rates of vaccination. The prevention of pertussis in infants presents several challenges, including the waning immunity of the acellular pertussis (aP) vaccine, the limited protection afforded to newborns before they complete the vaccine series, and the existence of gaps in maternal vaccination. Furthermore, the unwillingness or refusal of a considerable number of individuals, including some healthcare workers, to receive vaccinations represents another significant challenge.Areas covered: This narrative review provides an updated overview of the ongoing challenge of preventing pertussis in infants and discusses some possible solutions.Expert opinion: The ongoing challenge of preventing pertussis in infants is multifaceted. To address these challenging issues, a multi-pronged approach is required. This approach should be designed to address various barriers and increase uptake. It should include measures to strengthen maternal vaccination programs, ensure timely infant vaccinations, improve public education, and continue research into more effective vaccines with longer-lasting immunity.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"247-263"},"PeriodicalIF":4.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143572561","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Analysis of bacterial spectrum and construction of a predictive model for postoperative sepsis in patients with upper urinary calculi and positive urinary cultures. 上尿路结石和尿培养阳性患者术后脓毒症的细菌谱分析和预测模型的构建。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-01 Epub Date: 2025-03-27 DOI: 10.1080/14787210.2025.2484285

Yizhou Wang, Meng Gao, Minghui Liu, Jinbo Chen, Zewu Zhu

{"title":"Analysis of bacterial spectrum and construction of a predictive model for postoperative sepsis in patients with upper urinary calculi and positive urinary cultures.","authors":"Yizhou Wang, Meng Gao, Minghui Liu, Jinbo Chen, Zewu Zhu","doi":"10.1080/14787210.2025.2484285","DOIUrl":"10.1080/14787210.2025.2484285","url":null,"abstract":"Background: To analyze bacterial profiles, antibiotic resistance, and urosepsis risk factors in urine culture-positive (UC+) patients post-endoscopic lithotripsy.Research design and method: Retrospectively, 806 UC+ patients (2016.3-2021.3) were stratified into urosepsis/non-urosepsis groups per Sepsis-3 criteria.Results: Among 845 isolates (56 species), Escherichia coli dominated (46.8%), followed by Enterococcus faecalis (8.8%). Gram-negative bacteria exhibited high resistance to ampicillin, cefazolin, and cefuroxime. Multivariate analysis identified preoperative multidrug-resistant (MDR) bacteriuria (OR = 2.15), staghorn calculi (OR = 2.23), days of preoperative antibiotics use <3 (OR = 1.87), absence of nephrostomy (OR = 2.30), and postoperative WBC > 9.8 × 109/L (OR = 2.69) as independent sepsis predictors. A nomogram incorporating these factors achieved robust predictive accuracy. Preoperative antibiotic use for ≥3 days was inversely correlated with the risk of urinary sepsis as the duration of antibiotic administration increased.Conclusions: Urosepsis incidence was 13.1% post-lithotripsy. Early risk stratification, targeted infection control, and antibiotic stewardship guided by urine susceptibility testing are critical for prevention.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"315-322"},"PeriodicalIF":4.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143691482","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Suppressive antibiotic treatment (SAT) in the era of MDRO infections: a narrative review. MDRO感染时代的抑制性抗生素治疗（SAT）：叙述性回顾。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-01 Epub Date: 2025-03-04 DOI: 10.1080/14787210.2025.2473077

Valentina Fornari, Guido Accardo, Tommaso Lupia, Francesco Giuseppe De Rosa, Silvia Corcione

{"title":"Suppressive antibiotic treatment (SAT) in the era of MDRO infections: a narrative review.","authors":"Valentina Fornari, Guido Accardo, Tommaso Lupia, Francesco Giuseppe De Rosa, Silvia Corcione","doi":"10.1080/14787210.2025.2473077","DOIUrl":"10.1080/14787210.2025.2473077","url":null,"abstract":"Introduction: Antibiotics were originally developed to treat acute bacterial infections, and research studies focus their efforts on safety and efficacy in the short term; however, prolonged course of antibiotics has been documented in multiple clinical settings. The aim of this narrative review is to provide a new perspective on SAT and to discuss new therapeuticpossibilities.Areas covered: We discuss new clinical scenarios in which SAT could be considered. We provided a broad discussion about long-acting agents and new or repurposed oral agents as well as the use of OPAT with elastomeric pumps and an overview of the pipeline of new antifungals. Limitations of SAT are presented in this review and especially patients' adherence issues, possible spread of MDROs, possible rising of the incidence of Clostridioides difficile infections, drug-to-drug interactions and drug-related problems, cost-effectiveness evaluation issues.Expert opinion: Many research gaps are evident and further studies are needed. Above all, the efficacy and safety of SAT in the different clinical scenarios. Discovery of new molecules against MDROs and ongoing research on PK/PD variables as well as a better understanding of the relationship between SAT and the emergence of resistance could improve SAT usage and reduce the impact of DRPs.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"291-303"},"PeriodicalIF":4.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143523045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effective antimicrobial therapies needed for treatment of severe infections in African newborns. 需要有效的抗菌药物治疗非洲新生儿的严重感染。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-01 Epub Date: 2025-04-01 DOI: 10.1080/14787210.2025.2484281

Pui-Ying Iroh Tam, Adrie Bekker, Julia Anna Bielicki, Olufunke Bolaji, Gwendoline Chimhini, Ziyaad Dangor, Felicity Fitzgerald, Nelesh Govender, Sandi Holgate, Gugulabatembunamahlubi Tj Kali, Uduak Okomo, Tochi Okwor, Charlene Rodrigues, Sithembiso Velaphi, Andrew Whitelaw, Angela Dramowski

引用次数: 0

Gram-positive infections in special populations. Expert view on the role of dalbavancin. 特殊人群中的革兰氏阳性感染。专家对达尔巴旺辛作用的看法。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-01 Epub Date: 2025-03-24 DOI: 10.1080/14787210.2025.2477196

Beatriz Sobrino, Sonia Luque, Eneritz Velasco-Arnaiz, Rubén Lovatti González, José Luis Del Pozo

{"title":"Gram-positive infections in special populations. Expert view on the role of dalbavancin.","authors":"Beatriz Sobrino, Sonia Luque, Eneritz Velasco-Arnaiz, Rubén Lovatti González, José Luis Del Pozo","doi":"10.1080/14787210.2025.2477196","DOIUrl":"10.1080/14787210.2025.2477196","url":null,"abstract":"Introduction: This review considers special populations as those patients for whom Gram-positive infections are particularly challenging to treat. We examine the potential benefits of dalbavancin in these patients.Areas covered: We focus on patients with renal impairment, hepatic failure or obesity, and, also, pediatric patients, elderly patients and socially vulnerable individuals. Five independent experts conducted exhaustive literature searches on PubMed. Papers were selected for inclusion according to their relevance to the topic. For each special population, we outline the most significant characteristics for infection management, describing the challenges of the most frequent Gram-positive infections, and reviewing the potential role of dalbavancin.Expert opinion: Dalbavancin may be a valid alternative to overcome the difficulties of infection management in these populations. We hope our insights will prove useful for patient-centered care. A long half-life, evidence-based efficacy and good safety profile make dalbavancin an adequate option, particularly for patients for whom oral treatment or continued IV access may be challenging, or those for whom hospital stay is more impactful. [Figure: see text].","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"265-275"},"PeriodicalIF":4.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143596542","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Recurrence of group B streptococcal infections in infants: a systematic review. 婴儿B群链球菌感染的复发：一项系统综述。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-01 Epub Date: 2025-03-10 DOI: 10.1080/14787210.2025.2474569

Francesca Miselli, Alessandra Boncompagni, Riccardo Cuoghi Costantini, Tommaso Zini, Luca Bedetti, Martina Buttera, Lucia Corso, Roberta Creti, Isotta Guidotti, Cecilia Rossi, Eugenio Spaggiari, Licia Lugli, Alberto Berardi

{"title":"Recurrence of group B streptococcal infections in infants: a systematic review.","authors":"Francesca Miselli, Alessandra Boncompagni, Riccardo Cuoghi Costantini, Tommaso Zini, Luca Bedetti, Martina Buttera, Lucia Corso, Roberta Creti, Isotta Guidotti, Cecilia Rossi, Eugenio Spaggiari, Licia Lugli, Alberto Berardi","doi":"10.1080/14787210.2025.2474569","DOIUrl":"10.1080/14787210.2025.2474569","url":null,"abstract":"Introduction: Group-B Streptococcus(GBS) infections may rarely recur after antibiotic treatment. We aimed to fill existing gaps on epidemiology, clinical features, and outcomes of GBS recurrences.Methods: A systematic search of PubMed and Embase was conducted, covering the period until 1 July 2024. The demographics, clinical characteristics, treatment, and outcomes of infants withGBS recurrence were analyzed. Recurrence was defined as > 1 episode of invasiveGBS infection (positive blood and/or cerebrospinal fluid culture), occurring after the completion of treatment for the initial episode.Results: Among the 213 recurrences, 146 reported individual data and were included in the analysis. GBS recurrences developed shortly after the completion of antibiotic treatment for the initial infection (median = 10 days 95%CI 6.0-18.8). Most infants were preterm (63.5%) and had received an adequately long course of antibiotics for the initial infection (median = 13 days, 95%CI 10-14). Serotype III waspredominant. Breast milk yielded GBS in most samples cultured (41/62, 66%); 5/15 (33%) infants who discontinued breastfeeding after recurrence had further GBS recurrence. Case fatalities were 3.7%.Conclusions: Preterm birth is closely associated with GBS recurrences. Adequately long courses of antibiotics or withdrawal of breast milk may not be useful measures to prevent recurrences.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"305-314"},"PeriodicalIF":4.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143585354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Past, present, and future perspectives on aztreonam and avibactam. 阿唑南和阿维巴坦的过去、现在和未来展望。

IF 4.2 2区医学

Expert Review of Anti-infective Therapy Pub Date : 2025-05-01 Epub Date: 2025-03-04 DOI: 10.1080/14787210.2025.2473047

Karen Bush

{"title":"Past, present, and future perspectives on aztreonam and avibactam.","authors":"Karen Bush","doi":"10.1080/14787210.2025.2473047","DOIUrl":"10.1080/14787210.2025.2473047","url":null,"abstract":"Introduction: Aztreonam is a monobactam antibiotic approved in 1986 to treat infections caused by aerobic Gram-negative bacteria, but, together with cephalosporins, lost clinical utility due to the emergence of extended-spectrum β-lactamases (ESBLs) and novel (serine) carbapenemases. Avibactam was the first in a novel non-β-lactam β-lactamase inhibitor class to effectively inhibit these enzymes. It has been approved in combination with ceftazidime to treat Gram-negative infections caused by bacteria that produce AmpC, ESBLs and serine carbapenemases, and with aztreonam to treat patients infected with metallo-β-lactamase-producing enteric bacteria. Combinations of avibactam with ceftazidime and/or aztreonam have been used successfully to treat enteric pathogens producing multiple classes of β-lactamases.Areas covered: Development of aztreonam, avibactam, and avibactam combinations are placed into a historical perspective, based on both preclinical and clinical data. A search of MEDLINE (Ovid) was used to identify relevant literature.Expert opinion: Avibactam combined with ceftazidime and aztreonam in either dual or triple combinations provides the opportunity to treat previously untreatable Gram-negative infections that produce multiple β-lactamases. Aztreonam combinations should be particularly attractive, due to stability to metallo-β-lactamase hydrolysis and its safety advantage in treating penicillin-allergic patients. Other inhibitor combinations in development may challenge these combinations.","PeriodicalId":12213,"journal":{"name":"Expert Review of Anti-infective Therapy","volume":" ","pages":"277-290"},"PeriodicalIF":4.2,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143515213","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0